• TRM (USD/COP)COP 3,461.92 +1.37% +COP 46.82Colombia's official exchange rate (Financial Superintendence), valid Nov 21 to Nov 23
  • EuroCOP 3,804.64 +1.37% +COP 51.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
  • Mexican pesoCOP 181.56 +1.37% +COP 2.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
← Back to the community
General

Why are FTC consent orders forcing CVS Caremark and Express Scripts to tear down biosimilar rebate walls?

Federal Trade Commission consent orders with CVS Caremark, Express Scripts, and OptumRx are dismantling the opaque pharmacy benefit manager profit engine, forcing healthcare conglomerates to delink administrative fees from inflated Wholesale Acquisition Cost list prices and tear down the formulary rebate walls blocking lower-cost biosimilars.

For over a decade, the Big Three PBMs—controlling nearly 80% of U.S. prescription drug claims through vertically integrated insurers Cigna, UnitedHealth Group, and CVS Health—channeled manufacturer negotiations through offshore group purchasing organizations like Ascent Health Services, Zinc, and Emisar. By tying administrative fees and rebate guarantees to a drug's Wholesale Acquisition Cost, PBMs created a perverse incentive to favor high-list-price reference biologics over interchangeable biosimilars that carried 70% lower net prices. Whenever a competing biosimilar attempted to gain preferred formulary tier placement, incumbent manufacturers threatened to withdraw bundled rebates across their entire portfolio, erecting an impenetrable rebate wall.

Under the 2026 regulatory settlements, PBMs must pass manufacturer rebates directly to patients at the point of sale, offer employer plan sponsors transparent National Average Drug Acquisition Cost (NADAC) cost-plus contracts, and stop penalizing low-WAC medications. While eliminating spread pricing—where middlemen bill employers far more than they reimburse independent pharmacies—compresses legacy PBM margins, critics argue that without structural divestiture of PBM-owned specialty pharmacies, vertically integrated insurers will simply shift profits into new administrative fees.

Will the FTC's behavioral consent orders genuinely lower out-of-pocket prescription costs and accelerate biosimilar adoption, or is breaking up vertically integrated insurer-PBMs the only real fix?

How will FTC consent orders reshape the U.S. pharmacy benefit market?

0 votes

Comments

Be respectful. Comments reported by several people are hidden until a moderator reviews them.

You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.